Sucralfate 1 g Tablet, 60-count
🆔 Identity & classification
Where does this data come from?
🏷️ RxNorm drug class
This medicine belongs to the Aluminum Complex class.
Where does this data come from?
🏭 Manufacturer & labeler
Where does this data come from?
🩺 Clinical
Sucralfate is used to treat and prevent the return of duodenal ulcers (ulcers located in first part of the small intestine). Treatment with other medications, such as antibiotics, may also be necessary to treat and prevent the return of ulcers caused by a certain type of bacteria (H. pylori) Sucralfate is in a class of medications called protectants. It sticks to damaged ulcer tissue and protects against acid and enzymes so healing can occur.
Read the full MedlinePlus article ↗- Sucralfate helps heal a duodenal ulcer — that's an ulcer in the first part of your small intestine. It works by coating the ulcer like a protective bandage, shielding it from stoma...
- What exactly is sucralfate supposed to do for me?
- Yes, timing really does matter. You should take sucralfate on an empty stomach so it can stick directly to the ulcer lining. Taking it with food can get in the way of that. If you...
- When should I take sucralfate — does it matter if I take it with food?
Patient education
Supplement & herbal interactions
Some supplements/herbs that may interact with Sucralfate — tap one for details:
Sucralfate may be associated with lower levels of 1 nutrient — worth a chat with your pharmacist, not a cause for alarm.
Where does this data come from?
Ask a licensed pharmacist directly — free, answered by our team.
💊 What it looks like
Where does this data come from?
🧪 Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
UNII H3R47K3TBD
FD&C Blue No. 1 is a synthetic blue dye approved for use in foods and medicines. It serves as a colorant to give the medication its distinctive appearance and help with product identification.
-
UNII PN2ZH5LOQY
A synthetic red dye approved by the FDA for use in foods, medicines, and cosmetics. It serves as a colorant to make tablets, capsules, and liquids visually distinctive for product identification.
-
UNII 70097M6I30
Magnesium stearate is a salt made from magnesium and stearic acid, a fatty substance. It's used in tablets and capsules as a lubricant and glidant to help ingredients flow smoothly during manufacturing and prevent sticking.
-
UNII OP1R32D61U
Microcrystalline cellulose is a purified form of cellulose, a natural fiber from plant sources. It acts as a binder and filler in tablets and capsules, helping hold ingredients together and give the medicine its shape and size.
-
UNII O8232NY3SJ
A plant-based carbohydrate derived from corn kernels. It acts as a filler to add bulk, a binder to hold ingredients together, and a disintegrant to help the tablet break apart in your stomach for absorption.
5 inactive ingredients listed in the exact product block matched to this NDC.
Where does this data come from?
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
💲 Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per each | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | Not in the retail survey — common for institutional, discontinued, or low-volume packs. | |
| Medicaid paysCMS SDUD · 12 mo | No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data. | |
| Medicare drug plans payPart D · quarterly | No Part D plan price is available for this NDC in our data. | |
Where does this data come from?
🔁 Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Sucralfate 1 g 00093-2210-01 | Teva | 100 tablets | $0.172 | AB | Availability likely | — |
| Sucralfate 1 g 51079-0753-20 | Mylan | 100 tablets | $0.172 | AB | Availability likely | — |
| Sucralfate 1 g 59762-0401-01 | Mylan | 100 tablets | $0.172 | AB | Availability likely | — |
| Sucralfate 1 g 60219-1656-01 | Amneal | 100 tablets | $0.172 | AB | Availability likely | — |
| Sucralfate 1 g 62135-0436-90 | Chartwell | 90 tablets | $0.172 | AB | Availability likely | — |
| Sucralfate 1 g 69238-1656-01 | Amneal | 100 tablets | $0.172 | AB | Availability likely | — |
| Sucralfate 1 g 72578-0081-01 | Viona | 100 tablets | $0.172 | AB | Availability likely | — |
| Sucralfate 1 g 60687-0695-01 | American | 100 tablets | $0.179 | AB | Discontinued | — |
| Carafate 1 g 58914-0171-10 | Allergan, | 100 tablets | $4.733 | AB | Availability likely | — |
| Sucralfate 1 g 00615-4517-30 | NCS | 30 tablets | — | AB | Discontinued | — |
| Sucralfate 1 g 00615-8653-39 | NCS | 30 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 42291-0936-90 | AvKARE | 90 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 48433-0091-20 | Safecor | 100 tablets | — | AB | FDA listed | — |
| Sucralfate 1 gthis 50090-5287-00 | A-S | 60 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 50090-6455-00 | A-S | 60 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 51407-0881-90 | Golden | 90 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 51655-0031-52 | Northwind | 30 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 51655-0475-52 | Northwind | 30 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 55154-4379-00 | Cardinal | 10 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 63629-1307-00 | Bryant | 28 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 63629-9152-01 | Bryant | 100 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 63629-9153-01 | Bryant | 500 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 67046-1469-03 | Coupler | 30 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 67296-2147-04 | Redpharm | 40 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 68071-1749-01 | NuCare | 100 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 68071-3478-03 | NuCare | 30 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 68071-3812-03 | NuCare | 30 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 68788-8316-01 | Preferred | 100 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 68788-8779-03 | Preferred | 30 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 68788-8946-01 | Preferred | 100 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 70771-1833-01 | Zydus | 100 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 71335-2114-00 | Bryant | 28 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 71335-2461-00 | Bryant | 28 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 71335-2637-00 | Bryant | 28 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 71610-0017-60 | Aphena | 90 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 71610-0541-60 | Aphena | 90 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 72162-2264-01 | Bryant | 100 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 72189-0234-20 | DIRECT | 20 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 72189-0429-20 | Direct_Rx | 20 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 80425-0091-01 | Advanced | 30 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 80425-0188-01 | Advanced | 30 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 80425-0213-01 | Advanced | 30 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 80425-0377-01 | Advanced | 30 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 82804-0063-30 | Proficient | 30 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 82804-0102-30 | Proficient | 30 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 87063-0176-01 | ASCLEMED | 100 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 55154-0281-00 | Cardinal | 10 tablets | — | AB | FDA listed | — |
Where does this data come from?
⏳ Availability & generic status
FDA-approved generic versions are listed, and recent pricing/market data suggests they may be available — see Therapeutic equivalents.
Where does this data come from?
📊 Medicare Part D spend CMS · PART D · 2026 (Q1)
🔬 Reported adverse events (FAERS)
Top reported reactions
Age at onset
Reporter sex
Serious outcomes
Where does this data come from?
📦 Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Status |
|---|---|---|---|
| 50090-5287-00 You're viewing this | 60 TABLET in 1 BOTTLE (50090-5287-0) | 2020-10-22 | Active |
🧭 About this NDC listing & data coverage
What data is (and isn’t) available for this NDC — tap to expand
| NDC identity (package / product / labeler codes) | ✓ Available |
| Labeler | ✓ Available |
| Product & package description | ✓ Available |
| Marketing category & status | ✓ Available |
| Active ingredient / dosage form / route | ✓ Available |
| FDA label (SPL via DailyMed) | ✓ Available |
| Package photos | ✓ Available |
| Inactive ingredients (structured) | ✓ Available |
| NADAC pharmacy acquisition price (CMS) | — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey. |
| Orange Book / therapeutic-equivalence data | ✓ Available |
| HCPCS J-code billing crosswalk | — Not published for this NDC Most self-administered / retail products have no J-code — that is normal. |
| Medicaid utilization (CMS SDUD) | — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold. |
Questions about this listing
Why is there no price listed?
Is the NDC printed on the package the same as the 11-digit billing NDC?
What do the three segments of this NDC mean?
Is this package still being marketed?
Who lists this product with the FDA?
Do I need a prescription for this product?
Where does this data come from?
📄 Full prescribing information FDA SPL
🎯 Indications and Usage ▾
INDICATIONS AND USAGE Sucralfate is indicated in: Short-term treatment (up to 8 weeks) of active duodenal ulcer. While healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers.
⏱️ Dosage and Administration ▾
DOSAGE AND ADMINISTRATION Active Duodenal Ulcer : The recommended adult oral dosage for duodenal ulcer is 1 g four times per day on an empty stomach. Antacids may be prescribed as needed for relief of pain but should not be taken within one-half hour before or after sucralfate. While healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination.
Maintenance Therapy: The recommended adult oral dosage is 1 g twice a day. Elderly: In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy (See PRECAUTIONS Geriatric Use ). Call your doctor for medical advice about side effects.
You may report side effects to Greenstone LLC at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
⛔ Contraindications ▾
CONTRAINDICATIONS Sucralfate is contraindicated in patients with known hypersensitivity reactions to the active substance or to any of the excipients.
🤒 Adverse Reactions ▾
ADVERSE REACTIONS Adverse reactions to sucralfate in clinical trials were minor and only rarely led to discontinuation of the drug. In studies involving over 2,700 patients treated with sucralfate tablets, adverse effects were reported in 129 (4.7%). Constipation was the most frequent complaint (2%).
Other adverse effects reported in less than 0.5% of the patients are listed below by body system: Gastrointestinal: diarrhea, nausea, vomiting, gastric discomfort, indigestion, flatulence, dry mouth Dermatological: pruritus, rash Nervous System: dizziness, insomnia, sleepiness, vertigo Other: back pain, headache Post-marketing : cases of hypersensitivity have been reported with the use of sucralfate tablets, including dyspnea, lip swelling, pruritus, rash, and urticaria. Cases of anaphylactic reactions, bronchospasm, laryngeal edema, edema of the mouth, Pharyngeal edema, respiratory tract edema and swelling of the face have been reported with an unknown oral formulation of sucralfate.
Bezoars have been reported in patients treated with sucralfate. The majority of patients had underlying medical conditions that may predispose to bezoar formation (such as delayed gastric emptying) or were receiving concomitant enteral tube feedings. Inadvertent injection of insoluble sucralfate and its insoluble excipients has led to fatal complications, including pulmonary and cerebral emboli.
Sucralfate is not intended for intravenous administration.
🔄 Drug Interactions ▾
Drug Interactions Some studies have shown that simultaneous sucralfate administration in healthy volunteers reduced the extent of absorption (bioavailability) of single doses of the following: cimetidine, digoxin, fluoroquinolone antibiotics, ketoconazole, l-thyroxine, phenytoin, quinidine, ranitidine, tetracycline, and theophylline. Subtherapeutic prothrombin times with concomitant warfarin and sucralfate therapy have been reported in spontaneous and published case reports. However, two clinical studies have demonstrated no change in either serum warfarin concentration or prothrombin time with the addition of sucralfate to chronic warfarin therapy.
The mechanism of these interactions appears to be nonsystemic in nature, presumably resulting from sucralfate binding to the concomitant agent in the gastrointestinal tract. In all case studies to date (cimetidine, ciprofloxacin, digoxin, norfloxacin, ofloxacin, and ranitidine), dosing the concomitant medication 2 hours before sucralfate eliminated the interaction. Because of the potential of Sucralfate to alter the absorption of some drugs, Sucralfate should be administered separately from other drugs when alterations in bioavailability are felt to be critical.
In these cases, patients should be monitored appropriately.
🤰 Pregnancy ▾
Pregnancy Teratogenic effects Teratogenicity studies have been performed in mice, rats, and rabbits at doses up to 50 times the human dose and have revealed no evidence of harm to the fetus due to sucralfate. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.
🧒 Pediatric Use ▾
Pediatric Use Safety and effectiveness in pediatric patients have not been established.
🧓 Geriatric Use ▾
Geriatric Use Clinical studies of Sucralfate Tablets did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy (See DOSAGE AND ADMINISTRATION ).
This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function (See PRECAUTIONS Special Populations: Chronic Renal Failure and Dialysis Patients ). Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.
🆘 Overdosage ▾
OVERDOSAGE Due to limited experience in humans with overdosage of sucralfate, no specific treatment recommendations can be given. Acute oral toxicity studies in animals, however, using doses up to 12 g/kg body weight, could not find a lethal dose. Sucralfate is only minimally absorbed from the gastrointestinal tract.
Risks associated with acute overdosage should, therefore, be minimal. In rare reports describing sucralfate overdose, most patients remained asymptomatic. Those few reports where adverse events were described included symptoms of dyspepsia, abdominal pain, nausea, and vomiting.
🧬 Clinical Pharmacology ▾
CLINICAL PHARMACOLOGY Sucralfate is only minimally absorbed from the gastrointestinal tract. The small amounts of the sulfated disaccharide that are absorbed are excreted primarily in the urine. Although the mechanism of sucralfate’s ability to accelerate healing of duodenal ulcers remains to be fully defined, it is known that it exerts its effect through a local, rather than systemic, action.
The following observations also appear pertinent: 1. Studies in human subjects and with animal models of ulcer disease have shown that sucralfate forms an ulcer-adherent complex with proteinaceous exudate at the ulcer site. 2.
In vitro, a sucralfate-albumin film provides a barrier to diffusion of hydrogen ions. 3. In human subjects, sucralfate given in doses recommended for ulcer therapy inhibits pepsin activity in gastric juice by 32%.
4. In vitro, sucralfate adsorbs bile salts. These observations suggest that sucralfate’s antiulcer activity is the result of formation of an ulcer-adherent complex that covers the ulcer site and protects it against further attack by acid, pepsin, and bile salts.
There are approximately 14 to 16 mEq of acid-neutralizing capacity per 1 g dose of sucralfate.
📦 How Supplied / Storage and Handling ▾
HOW SUPPLIED Product: 50090-5287 NDC: 50090-5287-0 60 TABLET in a BOTTLE
📋 Description ▾
DESCRIPTION Sucralfate Tablets contain sucralfate and sucralfate is an α-D-glucopyranoside, β-D-fructofuranosyl-, octakis-(hydrogen sulfate), aluminum complex. Tablets for oral administration contain 1 g of sucralfate. Also contain: D & C Red #30 Lake, FD&C Blue #1 Lake, magnesium stearate, microcrystalline cellulose, and starch.
Therapeutic category: antiulcer. Sucralfate Tablets contain sucralfate and sucralfate is an α-D-glucopyranoside, β-D-fructofuranosyl-, octakis-(hydrogen sulfate), aluminum complex.